Foresite Labs Welcomes Dr. David Weinreich as Operating Partner
Foresite Labs Welcomes Dr. David Weinreich as Operating Partner
With more than 20 years of experience in drug development and clinical operations, Weinreich recently served as the EVP and head of global clinical development at Regeneron
SAN FRANCISCO–(BUSINESS WIRE)–Foresite Labs today announced the appointment of David Weinreich, MD, MBA, as an operating partner. He will also serve as senior advisor at Foresite Capital, the multi-stage healthcare and life sciences investment firm. With his 20 years of expertise in clinical development, drug commercialization and advancing therapies for patients in need, David will support Foresite Labs’ incubated companies, particularly their translational and clinical research commitments, and explore and initiate new programs and company concepts.
David joins Foresite Labs from Regeneron, where he was the executive vice president and head of global clinical development. During his tenure with the company, David managed programs across different therapeutic focus areas, including its successful Dupixent program and its COVID therapeutic antibody. Prior to Regeneron, he was the head of global development for specialty medicine at Bayer Pharmaceuticals and previously served as executive director and global product area leader (Angiogenesis) at Amgen. He earned a BS in Computer Engineering from Columbia University, an Executive MBA from Georgetown University and an MD from Boston University School of Medicine.
“David’s experience and proven results in leading the development and delivery of innovative medicines to patients in multiple therapeutic domains will be essential to our work at Foresite Labs,” said Dr. Vikram Bajaj, co-founder and CEO of Foresite Labs.
“Foresite Labs remains focused on putting patients first and creating new and impactful solutions to challenging medical conditions,” said David Weinreich, operating partner at Foresite Labs. “I’m eager to contribute the knowledge and skills I’ve gained throughout my career to advance the important work undertaken by each of Foresite Labs’ companies.”
Founded in 2019, Foresite Labs drives healthcare innovation by launching life sciences and healthcare companies that use the tools of data science to address our greatest unmet medical needs. Foresite Labs incubated companies include Alumis, TenSixteen Bio, Sestina Bio (acquired by Inscripta) and Interline Therapeutics.
To learn more about Foresite Labs, visit www.foresitelabs.com.
About Foresite Labs
Foresite Labs is a center for entrepreneurial innovation at the nexus of data science and healthcare. Based in San Francisco and Boston, Foresite Labs partners with next-generation healthcare entrepreneurs to launch life sciences and healthcare companies that use the tools of data science to solve our greatest unmet medical needs. For more information, please visit www.foresitelabs.com.
Contacts
Media Contact
Kayla Abbassi
VSC for Foresite Labs
foresite@vsc.co